Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA

British Journal of Pharmacology

Volumn 157, Issue 2, 2009, Pages 179-194

  Fattal, Elias ^a,b,c   Barratt, Gillian ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b CNRS   (France)

^c UNIV PARIS SUD   (France)

Author keywords

Antisense oligonucleotides; Cell penetration, nanoparticles; Microparticles, controlled release; Pharmacokinetics; Sirna

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; MICROSPHERE; NANOPARTICLE; POLYMER; SMALL INTERFERING RNA; ANTISENSE OLIGONUCLEOTIDE;

CONTROLLED RELEASE FORMULATION; DNA SEQUENCE; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG PENETRATION; GENE EXPRESSION; HUMAN; NANOTECHNOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; ANIMAL; DELAYED RELEASE FORMULATION;

ANIMALS; DELAYED-ACTION PREPARATIONS; HUMANS; NANOTECHNOLOGY; OLIGONUCLEOTIDES, ANTISENSE; RNA, SMALL INTERFERING;

EID: 68549104191     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00148.x     Document Type: Review

References (161)

1. Aagaard L, Rossi JJ (2007). RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 59: 75-86. (Pubitemid 46770900)
2. Agrawal S (1999). Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta 1489: 53-68.
3. Agrawal S, Temsamani J, Tang JY (1991). Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88: 7595-7599. (Pubitemid 21915200)
4. Agrawal S, TemsamaniJ, Galbraith W, Tang J (1995). Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 28: 7-16.
5. Akhtar S, Lewis KJ (1997). Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustainedrelease biodegradable polymer microspheres. Int J Pharm 151: 57-67. (Pubitemid 27212304)
6. Akinc A, Thomas M, Klibanov AM, Langer R (2005). Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med 7: 657-663. (Pubitemid 40744532)
7. Allerson CR, Sioufi N, Jarres R, Prakash TP, Naik N, Berdeja A et al. (2005). Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem 48: 901-904. (Pubitemid 40270434)
8. Ambros V (2004). The functions of animal microRNAs. Nature 431: 350-355.
9. Andersen MO, Howard KA, Paludan SR, Besenbacher F, Kjems J (2008). Delivery of siRNA from lyophilized polymeric surfaces. Biomaterials 29: 506-512. (Pubitemid 350103802)
10. Aukunuru JV, Ayalasomayajula SP, Kompella UB (2003). Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. / Pharm Pharmacol 55: 1199-1206. (Pubitemid 37180005)
11. Aynie I, Vauthier C, Chacun H, Fattal E, Couvreur P (1999). Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev 9: 301-312. (Pubitemid 29361064)
12. Baker BF, Lot SS, Condon TP, Cheng-Flournoy S, Lesnik EA, Sasmor HM et al. (1997). 2'-0-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-I) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation Initiation complex in human umbilical vein endothelial cells. J Biol Chem 272: 11994-12000. (Pubitemid 27202775)
13. Balland O, Saison-Behmoaras T, Garestier T (1996). Nanoparticles as carriers for antisense oligonucleotides. In: Gregoriadis G, McCormack B (eds). Targeting of Drugs 5: Strategies for Oligonucleotide and Gene Delivery in Therapy. Plenum Press: New York, pp. 131-142.
14. Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
15. Bartlett DW, Davis ME (2007). Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem 18: 456-468.
16. Bartlett DW, Davis ME (2008). Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol Bioeng 99: 975-985.
17. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME (2007). Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 104: 15549-15554. (Pubitemid 47502954)
18. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S et al. (2001). Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 98: 9237-9242. (Pubitemid 32743900)
19. Bertholon I, Hommel H, Labarre D, Vauthier C (2006). Properties of polysaccharides grafted on nanoparticles investigated by EPR. Langmuir 22: 5485-5490. (Pubitemid 43954530)
20. Berton M, Turelli P, Trono D, Stein CA, Allemann E, Gumy R (2001). Inhibition of HIV-1 in cell culture by oligonucleotide-loaded nanoparticles. Pharm Res 18: 1096-1101. (Pubitemid 32900393)
21. Bielinska A, Kukowska-Latallo JF, Johnson J, Tomalia DA, Baker JR Jr (1996). Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res 24: 2176-2182. (Pubitemid 26174562)
22. Bonnet ME, Erbacher P, Bolcato-Bellemin AL (2008). Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response. Pharm Res 25: 2972-2982.
23. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B et al. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and In vivo: polyethylenimine. Proc Natl Acad Sci USA 92: 7297-7301.
24. Boussif O, Zanta MA, Behr JP (1996). Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold. Gene Ther 3: 1074-1080. (Pubitemid 27036110)
25. Braasch DA, Jensen S, Liu Y, Kaur K, Arar K, White MA et al. (2003). RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42: 7967-7975. (Pubitemid 36807714)
26. Braasch DA, Paroo Z, Constantinescu A, Ren G, Oz OK, Mason RP et al. (2004). Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett 14: 1139-1143.
27. Butler M, Stecker K, Bennett CF (1997). Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest 77: 379-388. (Pubitemid 27465599)
28. Butler M, Crooke RM, Graham MJ, Lemonidis KM, Lougheed M, Murray SF et al (2000). Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice. J Pharmacol Exp Ther 292: 489-496. (Pubitemid 30067410)
29. Chavany C, Le Doan T, Couvreur P, Puisieux F, Helene C (1992). Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. Pharm Res 9: 441-449.
30. Chavany C, Saison-Behmoaras T, Le Doan T, Puisieux F, Couvreur P, Helene C (1994). Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm Res 11: 1370-1378. (Pubitemid 24287423)
31. Chemin I, Moradpour D, Wieland S, Offensperger WB, Walter E, Behr JP et al. (1998). Liver-directed gene transfer: a linear polyethlenimine derivative mediates highly efficient DNA delivery to primary hepatocytes in vitro and in vivo. J Viral Hepat 5: 369-375. (Pubitemid 28529876)
32. Chiu YL, Rana TM (2003). siRNA function in RNAi: a chemical modification analysis. RNA 9: 1034-1048. (Pubitemid 37093614)
33. Cleek RL, Rege AA, Denner LA, Eskin SG, Mikos AG (1997). Inhibition of smooth muscle cell growth in vitro by an antisense oligodeoxynucleotide released from poly(DL-lactic-co-glycolic acid) microparticles. J Biomed Mater Res 35: 525-530.
34. Cohen-Sacks H, Najajreh Y, Tchaikovski V, Gao G, Elazer V, Dahan R et al. (2002). Novel PDGFbetaR antisense encapsulated in polymeric nanospheres for the treatment of restenosis. Gene Ther 9: 1607-1616. (Pubitemid 35414523)
35. Corey DR (2007). RNA learns from antisense. Nat Chem Biol 3: 8-11.
36. Cossum PA, Sasmor H, Dellinger D, Truong L, Cummins L, Owens SR et al. (1993). Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after Intravenous administration to rats. J. Pharmacol Exp Ther 267: 1181-1190. (Pubitemid 24068683)
37. Couvreur P, Kante B, Roland M, Guiot P, Bauduin P, Speiser P (1979). Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J Pharm Pharmacol 31: 331-332. (Pubitemid 9207599)
38. Dapic V, Bates PJ, Trent JO, Rodger A, Thomas SD, Miller DM (2002). Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications. Biochemistry 41: 3676-3685. (Pubitemid 34224680)
39. De Rosa G, Quaglia F, La Rotonda MI, Appel M, Alphandary H, Fattal E (2002). Poly(lactide-co-glycolide) microspheres for the controlled release of oligonucleotide/polyethylenimine complexes. J Pharm Sci 91: 790-799. (Pubitemid 34639643)
40. De Rosa G, Bochot A, Quaglia F, Besnard M, Fattal E (2003a). A new delivery system for antisense therapy: PLGA microspheres encapsulating oligonucleotide/polyethyleneimine solid complexes. Int J Pharm 254: 89-93. (Pubitemid 36259817)
41. De Rosa G, Quaglia F, Bochot A, Ungaro F, Fattal E (2003b). Long-term release and improved intracellular penetration of oligonucleotidepolyethylenimine complexes entrapped in biodegradable microspheres. Biomacromolecules 4: 529-536. (Pubitemid 36701221)
42. De Rosa G, Maiuri MC, Ungaro F, De Stefano D, Quaglia F, La Rotonda MI et al. (2005). Enhanced intracellular uptake and inhibition of NF-kappaB activation by decoy oligonucleotide released from PLGA microspheres. J Gene Med 7: 771-781. (Pubitemid 40872863)
43. Delie F, Berton M, Allemann E, Gumy R (2001). Comparison of two methods of encapsulation of an oligonucleotide into poly(D,Llactic acid) particles. Int J Pharm 214: 25-30. (Pubitemid 32244073)
44. Dheur S, Dias N, van Aerschot A, Herdewijn P, Bettinger T, Remy JS et al. (1999). Polyethylenimine but not cationic lipid improves antisense activity of 3'-capped phosphodiester oligonucleotides. Antisense Nucleic Acid Drug Dev 9: 515-525. (Pubitemid 30040674)
45. Dias N, Dheur S, Nielsen PE, Gryaznov S, Van Aerschot A, Herdewijn P et al. (1999). Antisense PNA tridecamers targeted to the coding region of Ha-ras mRNA arrest polypeptide chain elongation. J Mol Biol 294: 403-416.
46. Dinauer N, Lochmann D, Demirhan I, Bouazzaoui A, Zimmer A, Chandra A et al. (2004). Intracellular tracking of protamine/ antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation. J Control Release 96: 497-507. (Pubitemid 38553927)
47. Dong L, Gao S, Diao H, Chen J, Zhang J (2008). Galactosylated low molecular weight chitosan as a carrier delivering oligonucleotides to Kupffer cells Instead of hepatocytes in vivo. J Biomed Mater Res A 84: 777-784. (Pubitemid 351237795)
48. Dykxhoorn DM, Lieberman J (2006). Knocking down disease with SiRNAs. Cell 126: 231-235.
49. Elmen J, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Y et al. (2005). Locked nucleic acid (LNA) mediated improvements In siRNA stability and functionality. Nucleic Acids Res 33: 439-447. (Pubitemid 40276964)
50. Eom KD, Park SM, Tran HD, Kim MS, Yu RN, Yoo H (2007). Dendritic alpha,epsilon-poly(L-lysine)s as delivery agents for antisense oligonucleotides. Pharm Res 24: 1581-1589.
51. Esau CC, Monia BP (2007). Therapeutic potential for microRNAs. Adv Drug Deliv Rev 59: 101-114.
52. Fattal E, Vauthier C, Aynie I, Nakada Y, Lambert G, Malvy C et al. (1998). Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides. J Control Release 53: 137-143. (Pubitemid 28218697)
53. Freytag T, Dashevsky A, Tillman L, Hardee GE, Bodmeier R (2000). Improvement of the encapsulation efficiency of oligonucleotidecontaining biodegradable microspheres. J Control Release 69: 197-207. (Pubitemid 30700423)
54. Geary RS, Watanabe TA, Truong L, Freier S, Lesnik EA, Sioufi NB et al. (2001). Pharmacokinetic properties of 2'-0-(2-methoxyethyl)modified oligonucleotide analogs in rats, f Pharmacol Exp Ther 296: 890-897. (Pubitemid 32187362)
55. Godard G, Boutorine AS, Saison-Behmoaras E, Helene C (1995). Antisense effects of cholesterol-oligodeoxynucleotide conjugates associated with poly(alkylcyanoacrylate) nanoparticles. Eur J Biochem 232: 404-410.
56. Gomes dos Santos AL, Bochot A, Doyle A, Tsapis N, Siepmann J, Siepmann F et al. (2006a). Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery. J Control Release 112: 369-381.
57. Gomes dos Santos AL, Bochot A, Tsapis N, Artzner F, Bejjani RA, Thillaye-Goldenberg B et al. (2006b). Oligonucleotidepolyethylenimine complexes targeting retinal cells: structural analysis and application to anti-TGFbeta-2 therapy. Pharm Res 23: 770-781.
58. Grayson AC, Doody AM, Putnam D (2006). Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm Res 23: 1868-1876. (Pubitemid 44200551)
59. Gryaznov S, Skorski T, Cucco C, Nieborowska-Skorska M, Chiu CY, Lloyd D et al. (1996). Oligonucleotide N3'->P5' phosphoramidates as antisense agents. Nucleic Acids Res 24: 1508-1514. (Pubitemid 26119680)
60. Gryaznov SM, Lloyd DH, Chen JK, Schultz RG, DeDionisio LA, Ratmeyer L et al. (1995). Oligonucleotide N3'->P5' phosphoramidates. Proc Natl Acad Sci USA 92: 5798-5802.
61. Grzelinski M, Urban-Klein B, Martens T, Lamszus K, Bakowsky U, Hobel S et al. (2006). RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects In glioblastoma xenografts. Hum Gene Ther 17: 751-766. (Pubitemid 44100720)
62. Hall AH, Wan J, Shaughnessy EE, Ramsay Shaw B, Alexander KA (2004). RNA interference using boranophosphate siRNAs: structureactivity relationships. Nucleic Acids Res 32: 5991-6000. (Pubitemid 40073994)
63. Hall AH, Wan J, Spesock A, Sergueeva Z, Shaw BR, Alexander KA (2006). High potency silencing by single-stranded boranophosphate siRNA. Nucleic Acids Res 34: 2773-2781. (Pubitemid 43985638)
64. Hanvey JC, Peffer NJ, Bisi JE, Thomson SA, Cadilla R, Josey JA et al. (1992). Antisense and antigene properties of peptide nucleic acids. Science 258: 1481-1485. (Pubitemid 23011003)
65. Harborth J, Elbashir SM, Vandenburgh K, Manninga H, Scaringe SA, Weber K et al. (2003). Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev 13: 83-105. (Pubitemid 36547202)
66. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S et al. (2000). Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156: 1363-1380. (Pubitemid 30660013)
67. Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK et al. (2007). Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Nati Acad Sci USA 104: 5715-5721. (Pubitemid 47175600)
68. Helin V, Gottikh M, Mishal Z, Subra F, Malvy C, Lavignon M (1999). Cell cycle-dependent distribution and specific inhibitory effect of vectorized antisense oligonucleotides in cell culture. Biochem Pharmacol 58: 95-107. (Pubitemid 29246078)
69. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MO et al. (2006). RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 14: 476-484. (Pubitemid 44296092)
70. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ (2005). Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 65: 8984-8992. (Pubitemid 41377390)
71. Ishii KJ, Takeshita F, Gursel I, Gursel M, Conover J, Nussenzweig A et al. (2002). Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. J Exp Med 196: 269-274. (Pubitemid 34787517)
72. Jepsen JS, Pfundheller HM, Lykkesfeldt AE (2004). Downregulation of p21(WAFl/CIPl) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA). Oligonucleotides 14: 147-156.
73. Junghans M, Kreuter J, Zimmer A (2000). Antisense delivery using protamine-oligonucleotide particles. Nucleic Adds Res 28: E45.
74. Junghans M, Kreuter J, Zimmer A (2001). Phosphodiester and phosphorothioate oligonucleotide condensation and preparation of antisense nanoparticles. Biochim Biophys Acta 1544: 177-188. (Pubitemid 32121856)
75. Kakizawa Y, Furukawa S, Kataoka K (2004). Block copolymer-coated calcium phosphate nanoparticles sensing intracellular environment for oligodeoxynucleotide and siRNA delivery. J Control Release 97: 345-356. (Pubitemid 38759491)
76. Kakizawa Y, Furukawa S, lshii A, Kataoka K (2006). Organic-inorganic hybrid-nanocarrier of siRNA constructing through the self-assembly of calcium phosphate and PEG-based block aniomer. J Control Release 111: 368-370.
77. Kang H, DeLong R, Fisher MH, Juliano RL (2005). Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm Res 22: 2099-2106. (Pubitemid 41821589)
78. Kataoka K, Itaka K, Nishiyama N, Yamasaki Y, Oishi M, Nagasaki Y (2005). Smart polymeric micelles as nanocarriers for oligonucleotides and siRNA delivery. Nucleic Acids Symp Ser (Oxf) 49: 17-18.
79. Katas H, Alpar HO (2006). Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release 115: 216-225. (Pubitemid 44559708)
80. Khan A, Sommer W, Fuxe K, Akhtar S (2000). Site-specific administration of antisense oligonucleotides using biodegradable polymer microspheres provides sustained delivery and improved subcellular biodistribution in the neostriatum of the rat brain. J Drug Target 8: 319-334. (Pubitemid 32186101)
81. Khan A, Benboubetra M, Sayyed PZ, Ng KW, Fox S, Beck G et al. (2004). Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J Drug Target 12: 393-404. (Pubitemid 39302465)
82. Kilic AC, Capan Y, Vural I, Gursoy RN, Dalkara T, Cuine A et al. (2005). Preparation and characterization of PLGA nanospheres for the targeted delivery of NR2B-specific antisense oligonucleotides to the NMDA receptors in the brain. J Microencapsul 22: 633-641. (Pubitemid 43102159)
83. Kratzer I, Wernig K, Panzenboeck U, Bernhart E, Reicher H, Wronski R et al. (2007). Apolipoproteln A-I coating of protamineoligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. J Control Release 117: 301-311. (Pubitemid 46216580)
84. Kraynack BA, Baker BF (2006). Small interfering RNAs containing full 2'-0-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2- dependent activity. RNA 12: 163-176.
85. Krieg AM (2006). Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5: 471-484. (Pubitemid 44136959)
86. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R et al. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549.
87. Kurreck J (2003). Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 270: 1628-1644.
88. Lambert G, Fattal E, Brehier A, Feger J, Couvreur P (1998). Effect of polyisobutylcyanoacrylate nanoparticles and lipofectin loaded with oligonucleotides on cell viability and PKC alpha neosynthesis in HepG2 cells. Biochimie 80: 969-976.
89. Lambert G, Bertrand JR, Fattal E, Subra F, Pinto-Alphandary H, Malvy C et al. (2000a). EWS fli-1 antisense nanocapsules inhibits Ewing sarcoma-related tumor in mice. Biochem Biophys Res Commun 279: 401-406. (Pubitemid 32016729)
90. Lambert G, Fattal E, Pinto-Alphandary H, GuIIk A, Couvreur P (2000b). Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm Res 17: 707-714. (Pubitemid 30670637)
91. Lambert G, Fattal E, Pinto-Alphandary H, Gulik A, Couvreur P (2001). Polyisobutylcyanoacrylate nanocapsules containing an aqueous core for the delivery of oligonucleotides. Int J Pharm 214: 13-16. (Pubitemid 32244070)
92. Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA (2004). In vivo activity of nuclease-resistant siRNAs. RNA 10: 766-771.
93. Lebedeva I, Benimetskaya L, Stein CA, Vilenchik M (2000). Cellular delivery of antisense oligonucleotides. Eur J Pharm Biopharm 50: 101-119.
94. Lee RC, Feinbaum RL, Ambros V (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854. (Pubitemid 24014542)
95. Lendvai G, Velikyan I, Bergstrom M, Estrada S, Laryea D, Valila M et al. (2005). Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-0-methyl phosphodiester oligonucleotides in normal rats. Eur j Pharm Sci 26: 26-38. (Pubitemid 41097258)
96. Levin AA (1999). A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1489: 69-84.
97. Lewis KJ, Irwin WJ, Akhtar S (1998). Development of a sustainedrelease biodegradable polymer delivery system for site-specific delivery of oligonucleotides: characterization of P(LA-GA) copolymer microspheres in vitro. J Drug Target 5: 291-302.
98. Li SD, Chen YC, Hackett MJ, Huang L (2008). Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 16: 163-169.
99. Li W, Szoka FC Jr (2007). Lipid-based nanoparticles for nucleic acid delivery. Pharm Res 24: 438-449. (Pubitemid 46295166)
100. Liu W, Yao K (2002). Chitosan and its derivatives-a promising nonviral vector for gene transfection. J Control Release 83: 1-11. (Pubitemid 35239810)
101. Liu X, Howard KA, Dong M, Andersen MO, Rahbek UL, Johnsen MG et al. (2007). The influence of polymeric properties on chitosan/ siRNA nanoparticle formulation and gene silencing. Biomaterials 28: 1280-1288. (Pubitemid 44816373)
102. Lochmann D, Weyermann J, Georgens C, Prassl R, Zimmer A (2005). Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: physicochemical characterization. Eur J Pharm Biopharm 59: 419-429. (Pubitemid 40342516)
103. Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C et al. (1989). Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 86: 3474-3478. (Pubitemid 19141813)
104. Maksimenko A, Malvy C, Lambert G, Bertrand JR, Fattal E, Macearlo J et al. (2003). Oligonucleotides targeted against a junction oncogene are made efficient by nanotechnologies. Pharm Res 20: 1565-1567. (Pubitemid 37268269)
105. Mao S, Neu M, Germershaus O, Merkel O, Sitterberg J, Bakowsky U et al. (2006). Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)graft-poly(ethylene glycol) block copolymer/SiRNA polyplexes. Bioconjug Chem 17: 1209-1218. (Pubitemid 44455329)
106. de Martimprey H, Bertrand JR, Fusco A, Santoro M, Couvreur P, Vauthier C et al. (2008). siRNA nanoformulation against the ret/ PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Res 36: e2.
107. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T (2004). Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell 15: 185-197. (Pubitemid 38950966)
108. Mok H, Park JW, Park TG (2007). Antisense oligodeoxynucleotideconjugated hyaluronic acid/protamine nanocomplexes for intracellular gene inhibition. Bioconjug Chem 18: 1483-1489. (Pubitemid 47464055)
109. Moser HE, Dervan PB (1987). Sequence-specific cleavage of double helical DNA by triple helix formation. Science 238: 645-650.
110. Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM (2007). Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine 3: 173-183. (Pubitemid 47332344)
111. Nakada Y, Fattal E, Foulquier M, Couvreur P (1996). Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice. Pharm Res 13: 38-43. (Pubitemid 26076294)
112. Oishi M, Nagasaki Y, Itaka K, Nishiyama N, Kataoka K (2005). Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J Am Chem Soc 127: 1624-1625. (Pubitemid 40229133)
113. Oishi M, Nagasaki Y, Nishiyama N, Itaka K, Takagi M, Shimamoto A et al. (2007). Enhanced growth inhibition of hepatic multicellular tumor spheroids by lactosylated polyethylene glycol)-siRNA conjugate formulated in PEGylated polyplexes. Chem Med Chem 2: 1290-1297.
114. Opanasopit P, Nishikawa M, Hashida M (2002). Factors affecting drug and gene delivery: effects of interaction with blood components. Cut Rev Ther Drug Carrier Syst 19: 191-233. (Pubitemid 36231520)
115. Oster CG, Kim N, Grode L, Barbu-Tudoran L, Schaper AK, Kaufmann SH et al. (2005). Cationic microparticles consisting of poly(lactideco-glycolide) and polyethylenimine as carriers systems for parental DNA vaccination. J Control Release 104: 359-377. (Pubitemid 40731493)
116. Owens DE 3rd, Peppas NA (2006). Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307: 93-102.
117. Pan B, Cui D, Sheng Y, Ozkan C, Gao F, He R et al. (2007). Dendrimermodified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res 67: 8156-8163.
118. Pillai RS, Artus CG, Filipowicz W (2004). Tethering of human Ago proteins to mRNA mimics the miRNA-mediated repression of protein synthesis. RNA 10: 1518-1525.
119. Plank C, Mechtler K, Szoka FC Jr, Wagner, E (1996). Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther 7: 1437-1446. (Pubitemid 26293564)
120. Putney SD, Brown J, Cucco C, Lee R, Skorski T, Leonetti C et al. (1999). Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide. Antisense Nucleic Acid Drug Dev 9: 451-458. (Pubitemid 29525111)
121. Roques C, Salmon A, Fiszman MY, Fattal E, Fromes Y (2007). Intrapericardial administration of novel DNA formulations based on thermosensitive Poloxamer 407 gel. Int J Pharm 331: 220-223. (Pubitemid 46216676)
122. Rutz M, Metzger J, Geliert T, Luppa P, Lipford GB, Wagner H et al. (2004). Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 34:2541-2550. (Pubitemid 39302811)
123. Sands H, Gorey-Feret LJ, Cocuzza AJ, Hobbs FW, Chidester D, Trainor GL (1994). Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol 45: 932-943. (Pubitemid 24155784)
124. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q Storm G et al. (2004). Cancer siRNA therapy by tumor selective delivery with ligandtargeted sterically stabilized nanoparticle. Nucleic Acids Res 32: e149.
125. Schneider T, Becker A, Ringe K, Reinhold A, Firsching R, Sabei BA (2008). Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles. J Neuroimmunol 195: 21-27.
126. Schwab G, Chavany C, Duroux I, Goubin G, Lebeau J, Helene C et al. (1994). Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc Natl Acad Sci USA 91: 10460-10464. (Pubitemid 24329017)
127. Schwartz DA, Wohlford-Lenane CL, Quinn TJ, Krieg AM (1999). Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. J Immunol 163: 224-231.
128. Shcharbin D, Pedziwiatr E, Chonco L, Bermejo-Martin JF, Ortega P, de la Mata FJ et al. (2007). Analysis of interaction between dendriplexes and bovine serum albumin. Biomacromolecules 8: 2059-2062.
129. Shcharbin D, Ottaviani MF, Cangiotti M, Przybyszewska M, Zaborski M, Bryszewska M (2008). Impact of PAMAM G2 and G6 dendrimers on bovine serum albumin (fatty acids free and loaded with different fatty acids). Colloids Surf B Biointerfaces 63: 27-33.
130. Shen XC, Zhou J, Liu X, Wu J, Qu F, Zhang ZL et al. (2007). Importance of size-to-charge ratio in construction of stable and uniform nanoscale RNA/dendrimer complexes. Org Biomol Chem 5: 3674-3681. (Pubitemid 350037134)
131. Singh M, Ugozzoli M, Briones M, Kazzaz J, Soenawan E, O'Hagan DT (2003). The effect of CTAB concentration in cationic PLG microparticles on DNA adsorption and in vivo performance. Pharm Res 20: 247-251. (Pubitemid 36269731)
132. Song JJ, Smith SK, Hannon GJ, Joshua-Tor L (2004). Crystal structure of Argonaute and its implications for RISC slicer activity. Science 305: 1434-1437. (Pubitemid 39167656)
133. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178. (Pubitemid 39545841)
134. Summerton J (1999). Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta 1489: 141-158.
135. Summerton J, Weller D (1997). Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7: 187-195. (Pubitemid 27323077)
136. Swayze EE, Siwkowski AM, Wancewicz EV, Migawa MT, Wyrzykiewicz TK, Hung G et al. (2007). Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res 35: 687-700. (Pubitemid 46232083)
137. Takashima Y, Saito R, Nakajima A, Oda M, Kimura A, Kanazawa T et al. (2007). Spray-drying preparation of microparticles containing cationic PLGA nanospheres as gene carriers for avoiding aggregation of nanospheres. Int J Pharm 343: 262-269. (Pubitemid 47321027)
138. Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y (1997). EWSFlil antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 99: 239-247. (Pubitemid 27053464)
139. Tondelli L, Ricca A, Laus M, Lelli M, Citro G (1998). Highly efficient cellular uptake of c-myb antisense oligonucleotides through specifically designed polymeric nanospheres. Nucleic Adds Res 26: 5425-5431. (Pubitemid 28542744)
140. Tondelli L, Ballestri M, Magnani L, Vivarelli D, Fini A, Cerasi A et al. (2003). Core-shell nanospheres for oligonucleotide delivery. V: adsorption/release behavior of 'stealth' nanospheres. J Biomater Sci Polym Ed 14: 1209-1227.
141. Torchilin VP, Zhou F, Huang L (1993). pHsensitive liposomes. J. Liposome Res 3: 201-255.
142. Toub N, Angiari C, Eboue D, Fattal E, TenuJP, Le Doan T et al. (2005). Cellular fate of oligonucleotides when delivered by nanocapsules of poly(isobutylcyanoacrylate). J Control Release 106: 209-213. (Pubitemid 41140095)
143. Toub N, Bertrand JR, Malvy C, Fattal E, Couvreur P (2006a). Antisense oligonucleotide nanocapsules efficiently inhibit EWS-FIi 1 expression in a
144. Toub N, Bertrand JR, Tamaddon A, Elhamess H, Hillaireau H, Maksimenko A et al. (2006b). Efficacy of siRNA nanocapsules targeted against the EWS-Flil oncogene in Ewing sarcoma. Pharm Res 23: 892-900. (Pubitemid 43781397)
145. Urban E, Noe CR (2003). Structural modifications of antisense oligonucleotides. Farmaco 58: 243-258.
146. Urban-Klein B, Werth S, Abuharbeld S, Czubayko F, Aigner A (2005). RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12: 461-466. (Pubitemid 40394299)
147. Vester B, Wengel J (2004). LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 43:13233-13241. (Pubitemid 39391124)
148. Vlassov VV, Balakireva LA, Yakubov LA (1994). Transport of oligonucleotides across natural and model membranes. Biochim Biophys Acta 1197: 95-108. (Pubitemid 24219067)
149. Wahlestedt C, Salmi P, Good L, KeIa J, Johnsson T, Hokfelt T et al. (2000). Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA 97: 5633-5638. (Pubitemid 30313770)
150. Walder RY, Walder JA (1988). Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA 85: 5011-5015.
151. Weyermann J, Lochmann D, Georgens C, Zimmer A (2005). Albuminprotamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect. Eur J Pharm Biopharm 59: 431-438. (Pubitemid 40342517)
152. Wiemer EA (2007). The role of microRNAs in cancer: no small matter. Eur J Cancer 43: 1529-1544.
153. Xu S, Dong M, Liu X, Howard KA, Kjems J, Besenbacher F (2007). Direct force measurements between siRNA and chitosan molecules using force spectroscopy. Biophys J 93: 952-959. (Pubitemid 47219787)
154. Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LV et al. (1989). Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc Natl Acad Sci USA 86: 6454-6458.
155. Yoo H, Sazani P, Juliano RL (1999). PAMAM. dendrimers as delivery agents for antisense oligonucleotides. Pharm Res 16: 1799-1804. (Pubitemid 30040693)
156. Yu RZ, Geary RS, Leeds JM, Watanabe T, Moore M, Fitchett J et al. (2001). Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J Pharm Sci 90: 182-193.
157. Yuan X, Li L, Rathinavelu A, Hao J, Narasimhan M, He M et al. (2006). SiRNA drug delivery by biodegradable polymeric nanoparticles. J Nanosci Nanotechnol 6: 2821-2828. (Pubitemid 44579952)
158. Zhang R, Diasio RB, Lu Z, Liu T, Jiang Z, Galbraith WM et al. (1995). Pharmacokinetics and tissue distribution in rats of an oligodeoxynudeotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol 49: 929-939.
159. Zhou J, Wu J, Hafdi N, Behr JP, Erbacher P, Peng L (2006). PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun (Camb) 22: 2362-2364. (Pubitemid 43846378)
160. Zhu X, Lu L, Currier BL, Windebank AJ, Yaszemski MJ (2002). Controlled release of NFkappaB decoy oligonucleotides from biodegradable polymer microparticles. Biomaterials 23: 2683-2692. (Pubitemid 34465729)
161. Zobel HP, Junghans M, Maienschein V, Werner D, Gilbert M, Zimmermann H et al. (2000). Enhanced antisense efficacy of oligonucleotides adsorbed to monomethylaminoethylmethacrylate methylmethacrylate copolymer nanoparticles. Eur J Pliarm Biopharm 49: 203-210. (Pubitemid 30229867)